UPDATE: Zimmer Biomet Holdings (ZBH) Tops Q4 EPS by 1c, Revenues Beat; Offers FY19 EPS Mid-Point Guidance Below Consensus
Zimmer Biomet Holdings (NYSE: ZBH) reported Q4 EPS of $2.18, versus $2.17 reported last year. Revenue for the quarter came in at $2.07 billion versus the consensus estimate of $2.06 billion.
"We are encouraged with the solid close to 2018, driven by strong fourth quarter performance in the Asia Pacific and Europe, Middle East and Africa regions, and in our Spine & CMF category," said Bryan Hanson, President and CEO of Zimmer Biomet. "Overall, our financial results for the full year were in-line with our expectations for the progress of the turnaround of the business, and increase our confidence in achieving our 2019 objectives. We look forward to delivering on our near-term commitments to transition to offense and drive enhanced shareholder value, including the launch of a number of exciting new products and platform technologies to expand our ecosystem of differentiated solutions."
GUIDANCE:
Zimmer Biomet Holdings sees FY2019 EPS of $7.70-$7.90, versus the consensus of $7.82.
For earnings history and earnings-related data on Zimmer Biomet Holdings (ZBH) click here.